Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Tullia C Bruno"'
Autor:
James L Gulley, Deborah Collyar, Pedro J Romero, Christian M Capitini, Leisha A Emens, Avery D Posey, Patrick Hwu, Jennifer A Wargo, Ann W Silk, Ana Carrizosa Anderson, Tullia C Bruno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antig
Externí odkaz:
https://doaj.org/article/ba0feaa1364741509df21dfe108b7d2c
Autor:
Christopher A Chuckran, Tullia C Bruno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Checkpoint blockade immunotherapy established a new paradigm in cancer treatment: for certain patients curative treatment requires immune reinvigoration. Despite this monumental advance, only 20%–30% of patients achieve an objective response to sta
Externí odkaz:
https://doaj.org/article/4c63cc756efa449daf9b583b14e83707
Autor:
Daniel J Zabransky, Christopher J Nirschl, Nicholas M Durham, Ben V Park, Christina M Ceccato, Tullia C Bruno, Ada J Tam, Derese Getnet, Charles G Drake
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e34547 (2012)
Helios, an Ikaros family transcription factor, is preferentially expressed at the mRNA and protein level in regulatory T cells. Helios expression previously appeared to be restricted to thymic-derived Treg. Consistent with recent data, we show here t
Externí odkaz:
https://doaj.org/article/bf78dfb5507b46cb832b8fcb32d0ddc4
Autor:
Sayali Onkar, Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin, April Sagan, Marion Joy, Hatice U. Osmanbeyoglu, Katherine L. Pogue-Geile, Priscilla F. McAuliffe, Peter C. Lucas, George C. Tseng, Adrian V. Lee, Tullia C. Bruno, Steffi Oesterreich, Dario A. A. Vignali
Publikováno v:
Nature Cancer. 4:516-534
Autor:
Ayana T. Ruffin, Housaiyin Li, Lazar Vujanovic, Dan P. Zandberg, Robert L. Ferris, Tullia C. Bruno
Publikováno v:
Nature Reviews Cancer. 23:173-188
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Lung cancer mortality represents the leading cause of cancer related deaths in the United States and worldwide. Almost half of these deaths occur in female patients, making lung cancer the most common cause of cancer mortality in women with a higher
Externí odkaz:
https://doaj.org/article/6926c1edd95d4d1894ac8ea390bac9ba
Autor:
Anthony R. Cillo, Elina Mukherjee, Nathanael G. Bailey, Sayali Onkar, Jessica Daley, Claudia Salgado, Xiang Li, Dongyan Liu, Sarangarajan Ranganathan, Melissa Burgess, John Sembrat, Kurt Weiss, Rebecca Watters, Tullia C. Bruno, Dario A.A. Vignali, Kelly M. Bailey
Publikováno v:
Clin Cancer Res
Purpose: Ewing sarcoma and osteosarcoma are primary bone sarcomas occurring most commonly in adolescents. Metastatic and relapsed disease are associated with dismal prognosis. Although effective for some soft tissue sarcomas, current immunotherapeuti
Autor:
Ashwin Somasundaram, Anthony R. Cillo, Caleb Lampenfeld, Creg J. Workman, Sheryl Kunning, Lauren Oliveri, Maria Velez, Sonali Joyce, Michael Calderon, Rebekah Dadey, Dhivyaa Rajasundaram, Daniel P. Normolle, Simon C. Watkins, James G. Herman, John M. Kirkwood, Evan J. Lipson, Robert L. Ferris, Tullia C. Bruno, Dario A.A. Vignali
Publikováno v:
Cancer Immunol Res
Many cancer patients do not develop a durable response to the current standard-of-care immunotherapies, despite substantial advances in targeting immune inhibitory receptors. A potential compounding issue, which may serve as an unappreciated, dominan
Autor:
Dario A.A. Vignali, Tullia C. Bruno, Robert L. Ferris, Evan J. Lipson, John M. Kirkwood, James G. Herman, Simon C. Watkins, Daniel P. Normolle, Dhivyaa Rajasundaram, Rebekah Dadey, Michael Calderon, Sonali Joyce, Maria Velez, Lauren Oliveri, Sheryl Kunning, Creg J. Workman, Caleb Lampenfeld, Anthony R. Cillo, Ashwin Somasundaram
Supplementary Data from Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68d13871b3cf1b46ea9183ef5677559a
https://doi.org/10.1158/2326-6066.22544399.v1
https://doi.org/10.1158/2326-6066.22544399.v1
Autor:
Dario A.A. Vignali, Tullia C. Bruno, Robert L. Ferris, Evan J. Lipson, John M. Kirkwood, James G. Herman, Simon C. Watkins, Daniel P. Normolle, Dhivyaa Rajasundaram, Rebekah Dadey, Michael Calderon, Sonali Joyce, Maria Velez, Lauren Oliveri, Sheryl Kunning, Creg J. Workman, Caleb Lampenfeld, Anthony R. Cillo, Ashwin Somasundaram
Many cancer patients do not develop a durable response to the current standard-of-care immunotherapies, despite substantial advances in targeting immune inhibitory receptors. A potential compounding issue, which may serve as an unappreciated, dominan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b05fcf9dd223d5a61e7bb44a68f9198
https://doi.org/10.1158/2326-6066.c.6550631.v1
https://doi.org/10.1158/2326-6066.c.6550631.v1